Comparison of Diagnostic Yield of a FISH Panel Against Conventional Cytogenetic Studies for Hematological Malignancies: A South Indian Referral Laboratory Analysis Of 201 Cases

Conclusions: In conclusion, FISH was found to be advantageous in only a subset of HMs and cannot completely replace CCS. Utilization of the two modalities in conjunction or independently should depend on the indicated HM for an optimal approach to detecting chromosomal aberrations. PMID: 29286619 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research

Related Links:

BREAST cancer symptoms and signs develop when a few cells in this area start to divide uncontrollably. The most common cancer in women, there are also rare cases of the cancer developing in men. Watch out for these warning signs of breast cancer.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
WARNING, GRAPHIC CONTENT: Sylvain Pharand, from Montreal, was told he had just six months to live when doctors told him a cyst in his left nostril was sinus and lymph node cancer.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Yu Tong, Tao Yu, Shiping Li, Fengyan Zhao, Junjie Ying, Yi Qu, Dezhi Mu
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Might certain benign thyroid conditions influence the risk for developing thyroid cancer? This new study looks at the possible connection.Journal of Clinical Endocrinology &Metabolism
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
This report tracked pediatric cancer incidence by type and state.Morbidity &Mortality Weekly Report
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news
AbstractPurpose of reviewRecent studies demonstrate that normal human tissues accumulate substantial numbers of somatic mutations with aging, to levels comparable to their corresponding cancers. If mutations cause cancer, how do tissues avoid cancer when mutations are unavoidable?Recent findingsThe small intestines (SI) and colon accumulate similar numbers of replication errors, but SI adenocarcinoma is much rarer than colorectal cancer. Both the small and large intestines are subdivided into millions of small neighborhoods (crypts) that are maintained by small numbers of stem cells. To explain the SI cancer paradox, four ...
Source: Current Pathobiology Reports - Category: Laboratory Medicine Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematolo...
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Myeloid Neoplasia, Lymphoid Neoplasia, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Micro-Abstract Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Teaser Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Fish | Genetics | Hematology | India Health | Laboratory Medicine | Leukemia | Myelodysplastic Syndrome | Myeloma | Study